Phio Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Phio Pharmaceuticals (PHIO) with a Buy rating and $14 price target Phio’s lead asset is PH-762 is an siRNA-based therapy formulated to safely inhibit PD-1 expression on T cells within the tumor microenvironment to drive anti-tumor activity, the analyst tells investors in a research note. The firm believes the company is “flying under the radar with investors” and has a bullish outlook for the stock.